ArticleEuropean journal of medical research2026
Fertility-sparing treatment for low-grade endometrial stromal sarcoma.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLittle is known about the oncologic results of patients with low-grade endometrial stromal sarcoma (LGESS) with fertility preservation. This study investigated the prognosis of fertility-sparing surgeries and relevant obstetrical outcomes.
methodsAll eligible patients in the study center were retrospectively reviewed if they consented to surgical treatment for primary LGESS from February 2012 to June 2019 in the study center. Follow-up of fertility and oncologic outcomes was carried out until June 1, 2020.
resultsAmong 135 patients who underwent surgical therapy for primary uterine LGESS, 21 (15.6%) and 42 (31.1%) underwent fertility-sparing surgery and ovarian preservation, respectively. After a median follow-up of 38.5 (range 5-98) months, differences were detected in the recurrence rates among patients with and without fertility-sparing surgery (47.6% vs 15.8%, p = 0.002) or with and without ovarian preservation (42.9% vs 10.8%, p < 0.001). Fertility-sparing surgery and ovarian preservation significantly increased the risk of recurrence in the entire cohort (hazard ratio [HR] 3.5 and 5.2, 95% confidence interval [CI] 1.6-7.6 and 2.4-11.3, p = 0.002 and < 0.001) and in stage I patients (HR 2.6 and 3.1, 95% CI 1.0-6.4 and 1.3-7.4, p = 0.041 and 0.011). No factor was found to be associated with increased mortality risk. Among the 9 patients who attempted pregnancy, 7 (77.8%) achieved 8 live births. All three advanced-stage patients who underwent fertility-sparing surgery experienced recurrence without successful conception.
conclusionsFertility-sparing surgery for LGESS results in a significantly increased risk of recurrence but not mortality and has promising results in terms of live births in stage I patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.